190 related articles for article (PubMed ID: 8754494)
1. [Expression of pS2 protein in breast cancer and its relationship with estrogen and progesterone receptors].
Díez Gibert O; Machuca I; Sebastián MA; Rosel P; Navarro MA
Med Clin (Barc); 1996 Jun; 107(3):90-2. PubMed ID: 8754494
[TBL] [Abstract][Full Text] [Related]
2. Messenger RNA determination of estrogen receptor, progesterone receptor, pS2, and plasminogen activator inhibitor-1 by competitive reverse transcription-polymerase chain reaction in human breast cancer.
Tong D; Schneeberger C; Czerwenka K; Schmutzler RK; Speiser P; Kucera E; Concin N; Kubista E; Leodolter S; Zeillinger R
Clin Cancer Res; 1999 Jun; 5(6):1497-502. PubMed ID: 10389938
[TBL] [Abstract][Full Text] [Related]
3. Cytosolic levels of estrogen-regulated pS2 protein in breast cancer: correlation with tumor proliferative activity.
Correale M; Paradiso A; Abbate I; Mangia A; Dragone CD; Tedone T; Filotico R; Schittulli F; De Lena M
Tumour Biol; 1993; 14(1):30-7. PubMed ID: 8493448
[TBL] [Abstract][Full Text] [Related]
4. Exon 5 deletion variant estrogen receptor messenger RNA expression in relation to tamoxifen resistance and progesterone receptor/pS2 status in human breast cancer.
Daffada AA; Johnston SR; Smith IE; Detre S; King N; Dowsett M
Cancer Res; 1995 Jan; 55(2):288-93. PubMed ID: 7812959
[TBL] [Abstract][Full Text] [Related]
5. Expression of pS2 estrogen-inducible protein in primary breast cancer.
Horiguchi J; Iino Y; Takei H
Oncology; 1996; 53(1):12-5. PubMed ID: 8570124
[TBL] [Abstract][Full Text] [Related]
6. pS2 expression and response to hormonal therapy in patients with advanced breast cancer.
Schwartz LH; Koerner FC; Edgerton SM; Sawicka JM; Rio MC; Bellocq JP; Chambon P; Thor AD
Cancer Res; 1991 Jan; 51(2):624-8. PubMed ID: 1985778
[TBL] [Abstract][Full Text] [Related]
7. Estrogen-regulated cut-off values of pS2 and cathepsin D expression in breast carcinomas.
Markićević M; Petrović A; Kanjer K; Nesković-Konstantinović Z; Nikolić-Vukosavujević D
Adv Exp Med Biol; 2008; 617():341-8. PubMed ID: 18497057
[TBL] [Abstract][Full Text] [Related]
8. Expression of pS2 protein and estrogen and progesterone receptor status in breast cancer.
Ioakim-Liossi A; Karakitsos P; Markopoulos C; Aroni K; Delivelioti K; Gogas J; Kyrkou K
Acta Cytol; 1997; 41(3):713-6. PubMed ID: 9167689
[TBL] [Abstract][Full Text] [Related]
9. PS2 expression in BRCA1-associated breast cancers.
Charafe-Jauffre E; Eisinger F; Mathoulin-Portier MP; Sobol H; Jacquemier J
Anticancer Res; 2001; 21(4B):2877-81. PubMed ID: 11712780
[TBL] [Abstract][Full Text] [Related]
10. Prediction of relapse and survival in breast cancer patients by pS2 protein status.
Foekens JA; Rio MC; Seguin P; van Putten WL; Fauque J; Nap M; Klijn JG; Chambon P
Cancer Res; 1990 Jul; 50(13):3832-7. PubMed ID: 2354435
[TBL] [Abstract][Full Text] [Related]
11. [Expression of pS2-protein in breast cancer].
Kawabata K; Watanabe K; Ozaki S
Rinsho Byori; 1996 Jul; 44(7):647-52. PubMed ID: 8741495
[TBL] [Abstract][Full Text] [Related]
12. pS2 in breast carcinoma: association with steroid hormone receptor status.
Nikolić-Vukosavljević D; Grujić-Adanja G; Janković R; Branković-Magić M; Polić D; Jovanović D; Mitrović L
Tumori; 1998; 84(6):691-4. PubMed ID: 10080679
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of the estrogen regulated pS2 protein in mammary tumors.
Pichon MF; Milgrom E
Crit Rev Oncol Hematol; 1993 Aug; 15(1):13-21. PubMed ID: 8240704
[TBL] [Abstract][Full Text] [Related]
14. pS2 protein and steroid hormone receptors in invasive breast carcinomas.
Koerner FC; Goldberg DE; Edgerton SM; Schwartz LH
Int J Cancer; 1992 Sep; 52(2):183-8. PubMed ID: 1521907
[TBL] [Abstract][Full Text] [Related]
15. pS2 (TFF1) levels in human breast cancer tumor samples: correlation with clinical and histological prognostic markers.
Gillesby BE; Zacharewski TR
Breast Cancer Res Treat; 1999 Aug; 56(3):253-65. PubMed ID: 10573116
[TBL] [Abstract][Full Text] [Related]
16. PS2 protein in breast carcinomas: cut-off value of estrogen-regulated expression.
Nikolić-Vukosavljević D; Grujić-Adanja G; Janković R; Nesković-Konstantinović Z; Branković-Magić M
Neoplasma; 2001; 48(1):1-6. PubMed ID: 11327531
[TBL] [Abstract][Full Text] [Related]
17. [PS2 as a prognostic factor in 1065 cases of human breast cancer. A multicenter study].
Besse G; Kwiatkowski F; Gaillard G; Daver A; Dalifard I; Basuyau JP; Brunelle P; Wafflart J; Angibeau RM; Auvray E
Bull Cancer; 1994 Apr; 81(4):289-96. PubMed ID: 7703545
[TBL] [Abstract][Full Text] [Related]
18. [Breast carcinoma: evaluation of hormone receptors and pS2, erb-B2, P-glycoprotein and Ki-67 markers].
Abadjian G; Antoun R
J Med Liban; 1996; 44(1):10-5. PubMed ID: 8965315
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of ER, PR, MIB-1, pS2, and nuclear grade in FNA specimens of cT1 breast carcinomas: clinicopathological correlation.
Angelidou E; Politi E; Sotiropoulou G; Poulianou E; Koutselini H
Diagn Cytopathol; 2006 Aug; 34(8):547-52. PubMed ID: 16850494
[TBL] [Abstract][Full Text] [Related]
20. Cytosolic levels of TFF1/pS2 in breast cancer: Their relationship with clinical-pathological parameters and their prognostic significance.
Corte MD; Tamargo F; Alvarez A; Rodríguez JC; Vázquez J; Sánchez R; Lamelas ML; González LO; Allende MT; García-Muñiz JL; Fueyo A; Vizoso F
Breast Cancer Res Treat; 2006 Mar; 96(1):63-72. PubMed ID: 16267614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
